Histamine 2 receptor antagonists do not improve the outcomes of hospitalized COVID-19 patients

Histamine 2 receptor antagonists do not improve the outcomes of hospitalized COVID-19 patients

Saved in:

Bibliographic Details
Main Authors:	Waseem Amjad, Faisal Kamal, Adnan Malik, Ritu Singh, Sultan Mahmood
Format:	Article
Language:	English
Published:	Termedia Publishing House 2021-07-01
Series:	Gastroenterology Review
Subjects:	coronavirus disease 2019 h2 receptor blocker proton pump inhibitors.
Online Access:	https://www.termedia.pl/Histamine-2-receptor-antagonists-do-not-improve-the-outcomes-of-hospitalized-COVID-19-patients,41,44707,1,1.html
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Antisecretory treatment efficacy by proton pump inhibitors at gastroduodenal ulcer bleedings
by: M. A. Evseyev, et al.
Published: (2010-06-01)

Vonoprazan a novel potassium competitive acid blocker; another leap forward
by: Maha Elsabaawy, et al.
Published: (2024-05-01)

Current Trends in Treatment for Acid-Dependent Diseases: Clinical Efficacy and Safety of Rabeprazole
by: O. D. Lopina, et al.
Published: (2021-12-01)

The role of pH in symptomatic relief and effective treatment of gastroesophageal reflux disease
by: Anita Gąsiorowska
Published: (2017-12-01)

Effect of angiotensin-converting enzyme inhibitors versus that of angiotensin receptor blockers on survival in patients undergoing hemodialysis: a nationwide observational cohort study
by: Seok Hui Kang, et al.
Published: (2024-12-01)

Gastroesophageal reflux disease, resistant to proton pump inhibitors
by: V. O. Kaybysheva, et al.
Published: (2011-06-01)

Pharmaceutical hemostasis at peptic ulcer bleeding: state-of-the-art and perspectives
by: A. A. Schegolev, et al.
Published: (2013-07-01)

<i>H. pylori</i> eradication therapy for patients receiving nonsteroid antiinflammatory drugs
by: V. T. Ivashkin, et al.
Published: (2012-11-01)

Characteristics in Molecular Vibrational Frequency Patterns between Agonists and Antagonists of Histamine Receptors
by: S. June Oh
Published: (2012-06-01)

Change in Symptoms and Mucosal Findings after Proton Pump Inhibitor in Patients with Laryngopharyngeal Reflux
by: Min Woo Park, et al.
Published: (2025-01-01)

Which is the best choice for Helicobacter pylori eradication? Dual therapy or quadruple therapy?
by: Elif Gram Bacaksız, et al.
Published: (2022-05-01)

Rationale and Design of a Randomized, Open‐Label, Parallel‐Group Study of Esaxerenone Versus Angiotensin Receptor Blockers in Older Patients With Uncontrolled Hypertension on Calcium Channel Blocker Monotherapy (ESCORT‐HT)
by: Kazuomi Kario, et al.
Published: (2025-01-01)

Proton pump inhibitors enhance chemosensitivity, promote apoptosis, and suppress migration of breast cancer cells
by: Ihraiz Worood G., et al.
Published: (2020-06-01)

Contemporary Approaches to the Treatment of Gastroesophageal Reflux Disease
by: Boris D. Starostin
Published: (2019-03-01)

Deprescribing and Optimal Selection of Proton Pump Inhibitors (Contributions of the 26th United Russian Gastroenterology Week)
by: V. T. Ivashkin, et al.
Published: (2020-12-01)

Diagnosis and Treatment of Peptic Ulcer in Adults (Clinical Guidelines of the Russian Gastroenterological Association, Russian Society of Colorectal Surgeons and the Russian Endoscopic Society)
by: V. T. Ivashkin, et al.
Published: (2020-04-01)

Efficacy and Safety of Dual Delayed-Release Formulation of Esomeprazole in Patients with Gastroesophageal Reflux Disease: A Multicenter, Prospective, Observational Study
by: Hyun Lim, et al.
Published: (2025-01-01)

Predictive Factors Associated with Inappropriate Intravenous Proton Pump Inhibitors Use in Hospitalized Patients: A Case-Control Study
by: Niveen Khoury, et al.
Published: (2024-12-01)

Comparison of clinical and pharmacodynamic features of proton pump inhibitors efficacy in gastroesophageal reflux disease
by: O. A. Storonova, et al.
Published: (2015-12-01)

Increase in treatment compliance reveals new options of treatment of gastroesophageal reflux disease
by: Yu. V. Yevsyutina, et al.
Published: (2015-05-01)

Clinical Guidelines of the Russian Gastroenterological Association on the Diagnostics and Treatment of Eosinophilic Esophagitis
by: V. T. Ivashkin, et al.
Published: (2019-01-01)

Patterns of outpatient proton‒pump inhibitors use among older adults in a duplicative health system: comparing public and private prescribing
by: Sónia Romano, et al.
Published: (2025-01-01)

Potassium-competitive acid blockers, a new therapeutic class, and their role in acid-related diseases: a narrative review
by: Gerson Domingues, et al.
Published: (2022-08-01)

Comparison of new secondgeneration H1 receptor blockers with some molecules; a study involving DFT, molecular docking, ADMET, biological target and activity
by: Velid Unsal, et al.
Published: (2025-01-01)

New opinion on the issue of proton pump inhibitor-refractory gastroesophageal reflux disease
by: Yu. V. Yevsyutina, et al.
Published: (2014-11-01)

Vonoprazan in the management of erosive oesophagitis and peptic ulcer-induced medication: a systematic review
by: Décio Chinzon, et al.
Published: (2021-12-01)

Inappropriate prescribing of drugs for peptic ulcer and gastro-esophageal reflux disease remains a matter of concern: Results from the LAPTOP-PPI cluster randomized trial
by: Manuela Casula, et al.
Published: (2025-01-01)

Role of Janus Kinase inhibitors in the management of pulmonary involvement due to Long COVID-19 disease: A case control study
by: Pawan Kumar Singh, et al.
Published: (2023-07-01)

The Effect of the Concurrent Use of Angiotensin-Converting Enzyme Inhibitors or Receptor Blockers on Toxicity and Outcomes in Patients Treated with Radiotherapy: A Systematic Review and Meta-Analysis
by: Wan-Chuen Liao, et al.
Published: (2025-01-01)

β-receptor blocker enhances anti-tumor immunity via inhibiting lactate-induced norepinephrine metabolism of macrophages during malignant pleural effusion
by: Ru Zhang, et al.
Published: (2025-01-01)

Gastrointestinal symptoms in patients with coronavirus disease 2019 (COVID-19) – friend or foe?
by: Konrad Lewandowski, et al.
Published: (2021-11-01)

Effects of Olopatadine Hydrochloride, a Histamine H𝟏 Receptor Antagonist, on Histamine-Induced Skin Responses
by: Takashi Hashimoto, et al.
Published: (2010-01-01)

Risk of stroke associated with proton pump inhibitor use among individuals with and without pre-existing cardiovascular diseases: a systematic review and meta-analysis
by: Muhammed Shabil, et al.
Published: (2025-01-01)

Potentials of 24-hour esophageal рН monitoring in diagnostics and treatment efficacy control of gastroesophageal reflux disease
by: N. L. Dzhakhaya, et al.
Published: (2012-02-01)

Consumption of proton pump inhibitors in outpatients of Gastroenterology Clinics in Khyber Pakhtunkhwa: evidence of inexpedient use
by: Muhammad Ashfaq, et al.
Published: (2024-05-01)

Recurrent bilateral idiopathic anterior uveitis with vitritis post Coronavirus Disease 2019 infection
by: Srinivasan Sanjay, et al.
Published: (2021-01-01)

Predictors of interferon-gamma release assay results and their association with COVID-19 infection outcomes
by: S.J.W. Kang, et al.
Published: (2024-10-01)

Collapsing Pattern Class-IV Lupus Nephritis Presenting as Posterior Reversible Encephalopathy Syndrome and Cardiac Tamponade: A Rare COVID-19 Sequelae
by: K Harshitha Reddy, et al.
Published: (2025-01-01)

Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs)
by: Qingjian He, et al.
Published: (2025-01-01)

Commonly prescribed medications and risk of pneumonia and all-cause mortality in people with idiopathic pulmonary fibrosis: a UK population-based cohort study
by: Ann D. Morgan, et al.
Published: (2025-01-01)